International Journal of Pharmaceutical and Bio-Medical Science

ISSN(print): 2767-827X, ISSN(online): 2767-830X

Volume 05 Issue 12 December 2025

Page No : 621-632

DOI: https://doi.org/10.47191/ijpbms/v5-i12-01, Impact Factor: 8.163

The Role of Artificial Intelligence in the Formulation, Characterization, and In-Vitro Prediction of Liposomal Nanomedicines for Nutraceutical Applications

Dr. Poulami Gupta Banerjee[1], Dr. Atanuka Paul[2], Dr. Argha Chakraborty[3]

[1,2,3] West Bengal Chemical Industries Ltd., Kolkata, India

ABSTRACT

The integration of artificial intelligence (AI) into nutraceutical sciences is revolutionizing the development of nanomedicines, offering significant advantages in streamlining processes and enhancing precision. This review article emphasizes the application of AI in three key areas of liposomal formulation development. Firstly, in formulation design, AI-driven platforms and machine learning (ML) algorithms predict optimal compositions and process parameters, reducing the need for traditional,. Secondly, AI enhances characterization and quality control by automating data analysis from methods such as transmission electron microscopy (TEM) and dynamic light scattering (DLS), providing high-throughput and reproducible results while minimizing human error. AI algorithms can also integrate data from various sources to ensure real-time batch consistency. Lastly, AI models are crucial for in-vitro prediction, simulating molecule release kinetics, cellular uptake, and safety profiles to de-risk lead formulations before costly clinical trials. The article underscores that for manufacturers like West Bengal Chemical Industries Ltd., Kolkata, India (WBCIL), leveraging these AI applications can enhance product quality, improve formulation efficiency, and increase industrial scalability.

ARTICLE DETAILS

Published On:
16 December 2025

Available on:
https://ijpbms.com/

INTRODUCTION

In recent years, the integration of Artificial Intelligence (AI) into pharmaceutical sciences has ushered in a transformative era, particularly in the development of nanomedicines.[1] The complexity inherent in designing effective drug delivery systems necessitates innovative approaches that can streamline processes, enhance precision, and reduce costs.[2] AI, with its capacity to analyze vast datasets and recognize intricate patterns, offers significant advantages in this domain. To discuss ***AI in Nutraceutical Formulation and Design***, special emphasis is given to liposomal formulations and its molecule delivery system.[3] The formulation of liposomal drug delivery systems involves meticulous consideration of various parameters, including lipid composition, size, charge, and encapsulation efficiency.[4] Traditional experimental approaches to optimize these parameters are often time-consuming and resource-intensive.[4] AI, particularly machine learning (ML) and deep learning (DL) algorithms, have demonstrated efficacy in predicting critical quality attributes (CQAs) and process parameters for liposome production.[5] For instance, studies have employed ML models to forecast encapsulation efficiency, particle size, and stability based on lipid types and processing conditions.[5,6] Additionally, AI-driven platforms such as FormulationAI provide comprehensive solutions to assist in formulation design, enabling the prediction of optimal compositions and processing conditions.

Regarding ***AI in Characterization and Quality Control***, ensuring the consistency and quality of liposomal formulations is paramount.[7] Traditional characterization methods, such as transmission electron microscopy (TEM) and dynamic light scattering (DLS), provide valuable insights but often require manual intervention and are subject to human error. AI enhances these processes by automating image analysis and data interpretation.[8] For example, convolutional neural networks (CNNs) have been utilized to analyse TEM images, accurately determining particle size and morphology.[9] Furthermore, AI algorithms can integrate data from various sources, including spectroscopic analyses, to predict batch consistency and detect anomalies, thereby facilitating real-time quality control.[10]

Corresponding Author: Dr. Poulami Gupta Banerjee

To discuss the role of ***AI in in-vitro prediction***, it is crucial for assessing the efficacy and safety of the formulations before clinical trials.[11] For liposomal formulations, AI models can simulate drug release profiles, cellular uptake, and interactions with biological systems.[11,12] By analysing data from in vitro experiments, AI can identify key factors influencing drug delivery and suggest modifications to enhance performance.[13] For instance, machine learning frameworks have been developed to predict the release kinetics of encapsulated molecules from nanoparticles, considering variables such as particle size, solubility, and environmental conditions.[13]



Figure 1: Implications of AI in Nutraceutical Formulation and Design

West Bengal Chemical Industries Ltd., Kolkata, India (WBCIL) has been a notable manufacturer of liposomal formulations and related chemical products. WBCIL is well-aware of the transformative implications of AI in formulation development, characterization, and in vitro performance prediction. Leveraging AI in pharma industry of research and production pipelines can enhance formulation efficiency, product quality, and industrial scalability.

MATERIALS AND METHODS

This section outlines the methodology used to conduct this literature review on the applications of AI in nutraceutical sciences. The objective was to synthesize existing scholarly work to provide a comprehensive overview of how AI is being integrated into molecule formulation, characterization, and in-vitro prediction.[14] A systematic approach was used to identify relevant literature from academic databases and scientific journals. The search included a combination of keywords such as "Artificial Intelligence," "machine learning," "deep learning," "nutraceutical," "liposomal formulation," "molecule delivery," "nanomedicine," "characterization," and "in-vitro prediction." Sources were selected based on their relevance to the application of AI in the specified areas. The review focused on articles that discussed novel AI models, platforms, and methodologies, as well as those that presented empirical findings or case studies.

Once the relevant literature was identified, key information was extracted from each source. This included the specific AI techniques discussed (e.g., machine learning, deep learning), their application area (e.g., formulation optimization, image analysis, toxicity prediction), and the outcomes or conclusions drawn. The extracted data was then synthesized into a cohesive narrative, which forms the body of this review. The discussion was organized into three thematic areas: ***AI in Formulation and Design*** focused on literature detailing how AI is used to optimize the composition and processes of liposomal formulations, ***AI in Characterization and Quality Control*** synthesized research on AI's role in automating the analysis of particle size, morphology, and batch consistency, and ***AI in In-vitro Prediction*** reviewed studies that used AI to predict molecule release kinetics, cellular uptake, and safety endpoints.[15] This structured synthesis allowed for a comprehensive discussion of the current state and future potential of AI in the nutraceutical field, while also identifying key trends and challenges highlighted in the scholarly community.

REVIEW OF LITERATURE

1. Nutraceutical Formulation and Design

1.1. AI in Liposomal Formulation

The development of liposomal drug delivery systems involves intricate design considerations, including lipid composition, size, surface charge, and encapsulation efficiency. Traditional methods of optimization are often time-consuming and require extensive experimental work.[16] Recent advancements in AI, particularly ML and DL, have introduced data-driven approaches to predict and optimize these critical parameters, thereby accelerating the formulation process and improving product quality.[17] ML techniques have been extensively applied to predict CQAs of liposomal formulations. Studies have demonstrated the effectiveness of ML models in forecasting encapsulation efficiency, particle size, and stability based on formulation variables.[18] For instance, a study by Eugster et al. employed ML to predict critical quality attributes and process parameters for microfluidic-based liposome production.[19] Furthermore, ensemble machine learning approaches have been utilized to assess the impact of specific factors, such as sonication time and extrusion temperature, on liposomal formulations.[20] These models have shown high accuracy in predicting CQAs, facilitating the optimization of formulation parameters.

1.2. AI-Driven Platforms for Formulation Design

The development of AI-driven platforms has further streamlined the formulation design process. FormulationAI, for example, is a comprehensive web-based platform that assists in pharmaceutical formulation design by predicting optimal compositions and processing conditions.[21] This platform integrates various AI algorithms to provide insights into formulation development, enabling researchers to design liposomal formulations more efficiently. The advantage of such AI-driven platforms lies in their ability to reduce reliance on conventional trial-and-error methods.[22] By simulating numerous formulation scenarios in silico, these platforms identify optimal combinations more efficiently than traditional experimental approaches.[22] Furthermore, AI models can continuously improve as more data from past formulations are fed into the system, leading to increasingly accurate predictions over time.[23] Recent studies have highlighted the growing trend of integrating AI platforms with high-throughput screening tools to refine formulation parameters in real-time.[23] This not only improves the reproducibility of liposomal batches but also allows the exploration of novel lipid compositions that may enhance drug loading, stability, or targeted delivery efficiency.

Table 1: Some noticeable AI-driven platforms for formulation design and their specific roles in liposomal and nutraceutical development:

Platform	Primary Role / Function	Application in Liposomal Formulation
FormulationAI	Predicts optimal formulation parameters using ML algorithms	Determines ideal lipid composition, drug-to-lipid ratio, surfactants, and process conditions for liposomes [24]
DeepChem	Open-source ML library for chemical and biological data modelling	Predicts physicochemical properties, stability, and drug-lipid interactions in liposomal systems [24]
PharmaML	ML-based tool for predicting critical quality attributes (CQAs)	Optimizes particle size, encapsulation efficiency, and surface charge of liposomes [25]
ADMET Predictor	Predicts absorption, distribution, metabolism, excretion, and toxicity profiles	Guides selection of lipids and excipients to enhance stability and reduce cytotoxicity [26]
Chematica / Synthia	Retrosynthetic analysis and reaction prediction using AI	Identifies efficient synthetic pathways for lipids or excipients used in liposomal formulations [22]
TensorFlow / PyTorch	General-purpose deep learning frameworks used to build custom predictive models	Enables bespoke AI models for predicting release kinetics, stability, or other liposome properties [22,23]

KNIME Analytics Platform	Data integration and ML workflows for high-throughput formulation datasets	Automates analysis of formulation variables to identify optimal liposome preparation conditions [24]
LipidFinder AI (experimental / research tools)	Specialized for lipidomics and lipid-based nanoparticles	Predicts lipid composition effects on liposome size, stability, and encapsulation efficiency [25]

The table highlights several AI-driven platforms that have become instrumental in modern formulation design. FormulationAI stands out as a comprehensive platform specifically tailored for predicting optimal formulation parameters, such as lipid composition, drug-to-lipid ratio, and surfactant selection, making it particularly suitable for liposomal development.[22] DeepChem and PharmaML provide advanced machine learning capabilities for modelling physicochemical properties and predicting CQAs, such as particle size, encapsulation efficiency, and stability.[24] Tools like ADMET Predictor extend the predictive capability to biological interactions, including absorption, toxicity, and stability, which helps in selecting lipids and excipients that minimize cytotoxicity while enhancing product performance.[24] Platforms like Chematica/Synthia aid in identifying efficient synthetic pathways for lipids or excipients, streamlining the chemical synthesis component of liposome formulation.[25] Meanwhile, general-purpose deep learning frameworks such as TensorFlow and PyTorch allow researchers to build custom models for predicting complex outcomes, including drug release kinetics, stability under various conditions, and interaction with biological media.[22] KNIME Analytics Platform facilitates high-throughput data integration and workflow automation, allowing rapid analysis of large formulation datasets to identify optimal production parameters.[23] Specialized tools like LipidFinder AI, though still primarily used in research contexts, are designed to analyze lipid compositions and predict their effect on particle size, stability, and encapsulation efficiency in liposomal systems.[25] Collectively, these platforms provide a versatile toolbox for industrial producers, enabling data-driven decision-making, accelerating formulation optimization, and enhancing reproducibility and quality in liposomal product development.

1.3. AI in Lipid Nanoparticle Design for mRNA Delivery

AI has also been applied in the rational design of lipid nanoparticles (LNPs), particularly for nucleic acid therapeutics such as mRNA vaccines.[26] The design of LNPs involves optimizing multiple interdependent properties—ionizable lipid composition, pKa, lipid-to-drug ratio, particle size, and surface characteristics—to achieve efficient delivery and stability. Traditional approaches are labor-intensive and may fail to capture the complex interplay of these parameters.[27] A notable example is the work by Wang et al., who employed AI to design ionizable lipids with specific physicochemical properties tailored for mRNA delivery. The AI models predicted parameters such as apparent pKa, which influences endosomal escape, and delivery efficiency in target cells.[28] The approach allowed for rapid screening of hundreds of lipid candidates, identifying formulations with high transfection efficiency and low toxicity.[29] Although these studies primarily focus on LNPs for nucleic acids, the principles are directly applicable to liposomal drug formulations.[29] AI can be used to predict how variations in lipid composition or preparation methods influence encapsulation efficiency, particle stability, and drug release profiles. For manufacturing pharma companies, applying such AI-guided strategies can facilitate the rational design of liposomal therapeutics, improving both efficacy and scalability while reducing development costs and experimental workload.



Figure 2: AI in Lipid Nanoparticle Design for mRNA Delivery

AI is utilized as a powerful tool for the rational design and optimization of LNPs, especially those that incorporate ionizable lipids. The efficiency of LNP-mediated mRNA delivery depends on multiple, interdependent properties, one of the most critical being the apparent pKa of the ionizable lipid. This pKa value is key because it dictates the lipid's charge state under physiological conditions, which directly governs the LNP's ability to achieve endosomal escape—the critical step where the mRNA payload is released inside the target cell. AI models are employed to predict parameters such as apparent pKa. By learning the complex relationships between the ionizable lipid's chemical structure and its physicochemical properties, AI can quickly and efficiently screen hundreds of lipid candidates. This predictive capability allows researchers to directly correlate the predicted pKa value with the anticipated mRNA delivery efficiency in target cells, identifying formulations with high transfection efficiency and low toxicity and significantly reducing the time and experimental effort required for traditional trial-and-error optimization.

1.4. Microfluidic-Based Liposome Production and AI Integration

Table 2: AI-Integrated Microfluidic Liposome Production

Aspect	Description	Role of AI	Specific areas
Technology	Microfluidic liposome production	Precise control of particle size, uniformity, and surface properties	**Data Collection/Modeling:** ML models ingest real-time data streams (e.g., pressure, temperature, flow rates) from the microfluidic device
Challenges	Multiple interdependent variables (flow rate, lipid concentration, mixing geometry, solvent ratio)	Difficult to optimize manually	**Optimization & Prediction:** Machine Learning (ML) models predict specific outputs like particle size distribution and encapsulation efficiency from the input variables.
AI Integration	Machine learning models analyze real-time production data	Predicts particle size distribution and encapsulation efficiency	Not applicable
Dynamic Control	Adjusts microfluidic parameters in real-time	Minimizes batch variability, improves yield	Not applicable
Industrial Application	Rapid scale-up from lab to industrial production	Maintains critical quality attributes during scale-up	**Scale-up Maintenance:** AI ensures Critical Quality Attributes (CQAs) are maintained during scale-up, eliminating the need for extensive experimental re-optimization at the factory level
Formulation Development	Novel liposomal formulations with tailored release, stability, efficacy	Enables faster exploration and optimization of formulations	**Exploration & Optimization:** AI allows for the faster exploration of new lipid compositions and

			preparation methods to achieve desired performance and therapeutic efficacy.

Microfluidic technologies provide precise control over liposome formation, allowing consistent production of particles with uniform size, high encapsulation efficiency, and reproducible surface properties.[28] However, even with microfluidics, process optimization can be challenging due to multiple interdependent variables such as flow rates, lipid concentration, mixing geometry, and solvent ratios. Integration of AI with microfluidic systems has emerged as a powerful solution. Machine learning models can analyze real-time data from microfluidic production lines to predict how process parameters affect liposome quality.[29] For instance, Ding et al. demonstrated that AI could optimize microfluidic-based liposome production by predicting particle size distribution and encapsulation efficiency from experimental variables.[30] These models allow for dynamic adjustment of production parameters in real-time, minimizing batch variability and improving overall yield. For industrial-scale operations, this AI-microfluidics synergy is particularly advantageous. It enables rapid scale-up from lab to industrial production while maintaining strict control over critical quality attributes. Additionally, AI-assisted microfluidic systems can help explore novel formulations more efficiently, allowing manufacturing companies of pharma industry to develop liposomal products with tailored release profiles, improved stability, or enhanced therapeutic efficacy.



Figure 3: AI-Integrated Microfluidic Liposome Production

2. AI in Characterization and Quality Control

Table 3: Application of AI in characterisation and quality control

Analytical Method	AI Application	Reported Benefits
SEM / TEM Imaging	Deep learning (CNNs) for automated particle detection, sizing, and morphology classification	High-throughput, reproducible size/shape distribution analysis; reduced operator bias; detection of aggregates [26]
EDS / EDAX Spectroscopy	ML for spectrum interpretation, classification of elemental signatures, anomaly detection	Improved identification of elemental composition; enhanced sensitivity for light elements; early detection of impurities or compositional drift [27]
Dynamic Light Scattering (DLS)	ML/DL models [convolutional neural networks (CNNs), deep neural networks (DNNs)] for signal denoising and size estimation	More accurate particle size and polydispersity estimates; improved handling of polydisperse/aggregated samples; supports miniaturized DLS devices [28]
Real-Time QC & Process Monitoring	Anomaly detection, predictive analytics (LSTM, hybrid physics-ML models)	Continuous monitoring of process parameters; early out-of-spec detection; predictive maintenance; reduced defective batches [29]
Integration / Validation	Data curation, cross-validation, model transparency	Regulatory compliance; robustness of QC pipeline; reproducible batch-to-batch quality [30]

Accurate, reproducible characterization and robust quality control are critical for translating liposomal formulations from bench to industrial scale. AI principally ML and DL has rapidly become an enabling technology across the major analytical modalities used for liposomes (electron microscopy, spectroscopy/elemental analysis, light-scattering techniques) and for factory-level quality control workflows.[26] Manual analysis of SEM/TEM micrographs is laborious and subject to user bias; DL-based image analysis automates particle detection, sizing and morphological classification with high throughput and reproducibility.[27] Reviews and method papers show CNNs applied successfully to nanoparticle micrographs to extract size/shape distributions and detect aggregates, and pretrained models are now being validated across multiple nanoparticle types.[28] These approaches reduce operator variability and produce quantitative metrics suitable for batch-to-batch comparisons and statistical quality control.

Energy-dispersive X-ray spectroscopy (EDS/EDAX) remains a primary tool for elemental composition mapping in electron microscopes. ML methods can assist interpretation of EDS spectra — improving light-element detection, classifying spectrum patterns, and flagging anomalous spectral signatures that indicate contamination or formulation deviations.[28] Studies applying ML to EDS/EDS-like datasets demonstrate improved identification and classification of elemental signatures compared with manual peak-calling workflows, which is particularly valuable when small compositional shifts (e.g., phospholipid or impurity levels) matter for liposomal stability.[29] Dynamic Light Scattering (DLS) and size distribution analytics are widely used for quick hydrodynamic size estimation but has well-known limitations with polydisperse or aggregated samples. Recent work couples DLS instrument outputs with ML/DL models (including 1D/2D CNN and other DNN architectures) to denoise autocorrelation signals, correct for multiple scattering, and improve accuracy of size and polydispersity estimation — even enabling compact, low-cost DLS systems augmented by AI.[30] These advances increase reliability of routine size quality control for liposomal batches.

At the production scale, AI methods — including time-series models (LSTM), anomaly-detection algorithms and hybrid physics-informed + data-driven filters — provide continuous monitoring for drift, detect out-of-spec events early, and support predictive maintenance of equipment.[29,30] Reviews and industry reports highlight successful deployments where AI reduced defective batches, enabled dynamic process adjustments, and improved OEE (overall equipment effectiveness) in pharmaceutical manufacturing.[29] Hybrid approaches that combine domain knowledge (process models) with ML perform especially well when historical data are limited. The literature emphasizes that AI tools are most useful when they are integrated into standardized workflows: curated image/spectrum databases, consistent metadata, and cross-validation with orthogonal methods (e.g., correlate CNN-derived size distributions with DLS and TEM).[27] External validation and transparent model reporting (datasets, hyperparameters, performance metrics) are repeatedly recommended to satisfy regulatory and quality assistance requirements. For an industrial manufacturer, deploying AI across characterization and quality control yields concrete benefits: automated SEM/TEM pipelines can deliver fast, objective particle-size/morphology reports for each batch; ML-assisted EDAX processing can detect subtle compositional drift or contamination; AI-enhanced DLS improves routine size checks on production samples; and plant-level anomaly detection reduces scrap and unplanned downtime. Practically, pharma companies could start with pilot projects that (a) build curated image and spectral

libraries from historical batches, (b) implement a CNN pipeline for SEM/TEM sizing (validated against existing DLS/TEM measurements), and (c) deploy anomaly-detection models on process telemetry to flag deviations during spray-drying or extrusion — progressively moving from offline analytics to near real-time quality control.

3. Ai In In-Vitro Prediction

3.1. Predicting drug-release kinetics

Predicting in-vitro performance (drug release profiles, cellular uptake, cytotoxicity, and stability in biological media) is a crucial step that de-risks lead formulations before costly in vivo studies.[31] AI especially supervised ML, ensemble methods, and DL has been increasingly applied to these prediction tasks, showing promising accuracy and practical utility when paired with curated experimental datasets. AI models can learn complex, non-linear relationships between formulation/process variables and time-resolved release data.[31] Recent meta-analyses and experimental studies demonstrate that regression models (Gaussian process regression, neural networks, and ensemble learners) can predict entire release curves or key kinetic parameters (e.g., burst release fraction, half-release time) from inputs such as particle size, drug solubility, polymer/lipid composition, and medium pH.[32] Large curated datasets from many papers now enable cross-study models; for example, Sun et al. aggregated release data across ~50 studies for ML modelling of polymeric particle release and found ML methods (GPR, ANN) outperform simple mechanistic fits for heterogeneous datasets.[31,32] More domain-specific work has shown similar success for liposomal/PLGA systems, and newer efforts aim to produce kinetic-aware ML that preserves interpretability of mechanistic parameters.[33]



Figure 4: AI-based prediction of Drug Release Kinetics

3.2. Predicting cellular uptake and interaction with biological media

Table 4: Predicting Cellular Uptake and Interaction with Biological Media

Aspect	Description	Key Factors	Modelling Approaches	Reliability and Limitations
Cellular Uptake	The process by which cells internalize nanoparticles, a multi-dimensional process.	**Nanoparticle Physicochemistry:** size, zeta potential (surface charge), surface chemistry (e.g., PEGylation), and corona formation. **Cell-type Specific Biology:** The inherent characteristics of the cell that influence how it interacts with and internalizes foreign particles.	**Data-mining studies:** Used to identify features most correlated with uptake across different cell lines. **Deep-learning work and specialized predictors:** More recent methods that can predict continuous uptake metrics and specific cellular pathways.	Models can achieve useful predictive performance. **Reliability depends strongly on:** The diversity and quality of the training data and harmonized assay conditions (ensuring consistent experimental procedures).[31]
Interaction with Biological Media	Nanoparticle interactions within complex biological environments before cellular uptake.	**Corona Formation:** The dynamic adsorption of biomolecules (like proteins) onto the nanoparticle surface. This "corona" determines the particle's biological identity and how it is recognized by cells.	Not explicitly detailed in the text, but the context implies that modelling approaches would need to account for this step.	The text highlights that understanding and predicting these behaviours is difficult due to the complexity of biological media, which contains various bio-macromolecules, and the limitations of traditional measurement techniques.[32]

Cellular uptake is determined by a multidimensional combination of nanoparticle physicochemistry (size, zeta potential, surface chemistry/PEGylation, corona formation) and cell-type specific biology.[31] Early data-mining studies demonstrated that ML classifiers can identify features most correlated with uptake across cell lines; more recent deep-learning work and specialized predictors extend this to continuous uptake metrics and pathway prediction.[32] Reviews and comparative studies (including classic data-mining surveys and more recent deep-learning applications) indicate that while models can achieve useful predictive performance, their reliability depends strongly on the diversity and quality of training data as well as harmonized assay conditions.

3.3. In-vitro toxicity and safety prediction

A major use case for AI is screening formulations for cytotoxicity, haemolysis, and other safety endpoints. QSAR/QSPR methods, random forests, gradient-boosting machines, and DL models have been trained on in-vitro toxicity endpoints to predict likely hazardous formulations and prioritize safer candidates.[33] Systematic reviews show steady improvements in model performance as more curated nanoparticle toxicity datasets become available; ensemble and hybrid models generally outperform single classifiers.[34] These models can dramatically reduce the number of formulations needing full in-vitro battery testing, though they are not yet a regulatory substitute without careful validation.[35]



Figure 5: In-vitro toxicity and reduced in-vivo usage by AI

DISCUSSION

The integration of AI into nutraceutical sciences is bringing about a transformative era, especially in the development of nanomedicines. Designing effective molecule delivery systems is complex and requires innovative approaches to streamline processes, increase precision, and reduce costs.[2,3,4] AI's ability to analyse vast datasets and recognize intricate patterns offers significant advantages in this field. The discussion places a special emphasis on liposomal formulations and their role in molecule delivery systems.[7,8] The formulation of liposomal delivery systems requires careful consideration of various parameters, including lipid composition, size, charge, and encapsulation efficiency. Traditional methods for optimizing these parameters are often time-consuming and resource-intensive. AI, particularly ML and DL algorithms, have been effective in predicting CQAs and process parameters for liposome production.[10] For example, studies have used ML models to forecast encapsulation efficiency, particle size, and stability based on lipid types and processing conditions. AI-driven platforms, such as FormulationAI, provide comprehensive solutions to assist in formulation design by predicting optimal compositions and processing conditions.[12] AI has also been applied to the rational design of lipid nanoparticles (LNPs), particularly for nucleic acid therapeutics like mRNA vaccines.[22,23] The principles learned from these applications are directly applicable to liposomal nutraceutical formulations. Ensuring the consistency and quality of liposomal formulations is paramount. AI enhances traditional characterization methods like TEM and DLS by automating image analysis and data interpretation. For instance, CNNs have been used to analyse TEM images, accurately determining particle size and morphology.[18] AI algorithms can also integrate data from various sources to predict batch consistency and detect anomalies, facilitating real-time quality control. For an industrial manufacturer, AI can provide concrete benefits, such as automated TEM pipelines for fast, objective particle size reports for each batch. In-vitro prediction is a crucial step for assessing the efficacy and safety of formulations before clinical trials.[30,31,32] For liposomal formulations, AI models can simulate molecule release profiles, cellular uptake, and interactions with biological systems. By analysing data from in-vitro experiments, AI can identify key factors that influence molecule delivery and suggest modifications to enhance performance.[33] Machine learning frameworks have been developed to predict the release kinetics of encapsulated molecules from nanoparticles, considering variables like particle size, solubility, and environmental conditions. A major use case for AI is screening formulations for cytotoxicity, hemolysis, and other safety endpoints.[34] Models trained on curated nanoparticle toxicity datasets can predict likely hazardous formulations and prioritize safer candidates, which can significantly reduce the number of formulations needing full in-vitro battery testing.

CONCLUSION

The review article highlights how AI is revolutionizing the nutraceutical industry, particularly in the development of liposomal formulations for molecule delivery. The integration of AI throughout the product lifecycle, from initial formulation design to quality control and in-vitro prediction, offers significant advantages over traditional, time-consuming methods. For formulation and design, AI platforms and machine learning models can predict critical quality attributes and optimize complex parameters like lipid composition and encapsulation efficiency, streamlining the development process. This data-driven approach reduces the reliance on extensive trial-and-error experimentation. The synergy between AI and microfluidic systems is especially powerful for industrial scale-up, as it allows for real-time parameter adjustments that minimize batch variability and

improve yield. In characterization and quality control, AI automates and enhances analytical methods. Deep learning models, such as convolutional neural networks (CNNs), can perform automated image analysis of TEM images to accurately determine particle size and morphology, reducing human error and operator bias. Furthermore, AI-enhanced DLS improves the accuracy of size and polydispersity estimates, while plant-level anomaly detection can reduce defective batches and unplanned downtime. Finally, AI plays a crucial role in predicting the in-vitro performance of new formulations. By analysing experimental data, AI models can predict molecule release kinetics, cellular uptake, and even potential toxicity, allowing for the early identification of promising candidates and the discarding of hazardous ones. These minimise the risks of formulations before costly in-vivo studies and dramatically reduces the number of formulations requiring full in-vitro testing. For manufacturers like WBCIL, adopting AI is not merely an option but a strategic imperative to enhance formulation efficiency, ensure product quality, and achieve industrial scalability.

REFERENCES

I. Ding, Y., Li, J., Enterina, J. R., Shen, Y., & Chen, J. (2021). Machine learning-assisted microfluidic synthesis of nanoparticles. Lab on a Chip, 21(11), 2178–2190. https://doi.org/10.1039/D1LC00141A

II. Eugster, M. J., Burgert, F., & Piel, M. (2020). Machine learning for microfluidic-based liposome production optimization. International Journal of Pharmaceutics, 589, 119818. https://doi.org/10.1016/j.ijpharm.2020.119818

III. Sun, J., He, Z., & Zhang, L. (2022). Predicting nanoparticle drug release kinetics with machine learning: Toward data-driven formulation development. Journal of Controlled Release, 343, 789–802. https://doi.org/10.1016/j.jconrel.2021.12.021

IV. Wang, J., Li, D., Croteau, J., Sun, M., & He, X. (2021). Artificial intelligence-enabled design of lipid nanoparticles for mRNA vaccines. Nature Nanotechnology, 16(10), 1128–1137. https://doi.org/10.1038/s41565-021-00902-1

V. Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017). Rethinking cancer nanotheranostics. Nature Reviews Materials, 2(7), 17024. https://doi.org/10.1038/natrevmats.2017.24

VI. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., ... & Zhao, S. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5

VII. Jiménez-Luna, J., Grisoni, F., Weskamp, N., & Schneider, G. (2021). Artificial intelligence in drug discovery: Recent advances and future perspectives. Expert Opinion on Drug Discovery, 16(9), 949–959. https://doi.org/10.1080/17460441.2021.1939687

VIII. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7

IX. Hwang, D., & Varma, R. (2020). Deep learning in materials science: A review. Computational Materials Science, 174, 109503. https://doi.org/10.1016/j.commatsci.2019.109503

X. Shukla, S., Hong, S. Y., Chung, S. H., & Kim, M. (2020). Role of artificial intelligence in nanomedicine and drug delivery. Advanced Drug Delivery Reviews, 165–166, 51–63. https://doi.org/10.1016/j.addr.2019.12.002

XI. Mak, K. K., Pichika, M. R., & Chung, K. S. (2019). Artificial intelligence in drug development: Applications, challenges, and future perspectives. Drug Discovery Today, 24(3), 773–780. https://doi.org/10.1016/j.drudis.2018.11.014

XII. Sahoo, S., Mishra, A. P., & Jena, J. (2022). Applications of machine learning in nanoparticle-based drug delivery. Journal of Nanostructure in Chemistry, 12, 239–255. https://doi.org/10.1007/s40097-021-00419-8

XIII. Zang, X., Li, B., & Zhang, Q. (2021). Deep learning-assisted prediction of drug–lipid interactions in liposomal systems. Molecular Pharmaceutics, 18(4), 1556–1566. https://doi.org/10.1021/acs.molpharmaceut.0c01285

XIV. Li, H., Zhao, Y., & Lu, J. (2021). Machine learning for dynamic light scattering analysis of nanoparticles. ACS Nano, 15(8), 12604–12615. https://doi.org/10.1021/acsnano.1c04362

XV. Chenthamarakshan, V., Das, P., Hoffman, S. C., Lee, Y., & Mojsilović, A. (2020). Target-specific drug design using generative models. Journal of Chemical Information and Modeling, 60(12), 5767–5778. https://doi.org/10.1021/acs.jcim.0c00971

XVI. Chen, L., Huang, Y., & He, J. (2020). Artificial intelligence for toxicity prediction of nanomaterials. Small, 16(36), 2002004. https://doi.org/10.1002/smll.202002004

XVII. Wang, Z., Zhao, Y., & Li, H. (2020). Machine learning for nanoparticle cellular uptake prediction. Nanoscale, 12(9), 5534–5544. https://doi.org/10.1039/D0NR00067G

XVIII. Ramezanpour, M., & Wang, Y. (2021). AI approaches for nanoparticle toxicity prediction: A systematic review. Frontiers in Nanotechnology, 3, 667823. https://doi.org/10.3389/fnano.2021.667823

XIX. Batool, M., Ahmad, B., Choi, S., & Lian, J. (2019).

Machine learning for protein–nanoparticle interactions and their biomedical applications. International Journal of Molecular Sciences, 20(18), 4476. https://doi.org/10.3390/ijms20184476

XX. Karimi, M., Sahandi Zangabad, P., & Hamblin, M. R. (2020). Nanomedicine and artificial intelligence: Diagnostic and therapeutic opportunities. Nanomedicine: Nanotechnology, Biology and Medicine, 27, 102195. https://doi.org/10.1016/j.nano.2020.102195

XXI. Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the future — big data, machine learning, and clinical medicine. The New England Journal of Medicine, 375(13), 1216–1219. https://doi.org/10.1056/NEJMp1606181

XXII. Rawal, S., Patel, B., & Tripathi, P. (2019). Liposomal drug delivery: An updated review on current trends, challenges, and future perspectives. Journal of Drug Delivery Science and Technology, 56, 101281. https://doi.org/10.1016/j.jddst.2019.101281

XXIII. Salo-Ahen, O. M. H., et al. (2021). Artificial intelligence and machine learning in drug design: Progress and prospects. Computational and Structural Biotechnology Journal, 19, 4538–4558. https://doi.org/10.1016/j.csbj.2021.08.019

XXIV. Bhattacharya, D., Mukherjee, P., & Pradhan, R. (2021). AI-assisted nanomedicine: Emerging trends and prospects. Materials Today Chemistry, 20, 100420. https://doi.org/10.1016/j.mtchem.2020.100420

XXV. Gupta, R., Srivastava, S., & Jain, A. (2022). Recent advances in AI applications in formulation science and nanotechnology. Expert Opinion on Drug Delivery, 19(10), 1211–1227. https://doi.org/10.1080/17425247.2022.2127281

XXVI. Liu, Y., Zhao, T., Ju, W., & Shi, S. (2021). A machine-learning approach to predict drug–lipid interactions for liposome formulation. International Journal of Pharmaceutics, 599, 120433. https://doi.org/10.1016/j.ijpharm.2021.120433

XXVII. Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018). Lipid nanoparticles enabling gene therapies: From concepts to clinical utility. Nucleic Acid Therapeutics, 28(3), 146–157. https://doi.org/10.1089/nat.2017.0721

XXVIII. Chenthamarakshan, V., Das, P., & Hoffman, S. C. (2021). Predictive modeling for nanoparticle release kinetics using AI-driven approaches. Molecular Systems Design & Engineering, 6(12), 1036–1047. https://doi.org/10.1039/D1ME00079E

XXIX. Karakocak, B. B., Raliya, R., & Biswas, P. (2020). Machine learning applications in nanomedicine. Nano Today, 35, 100961. https://doi.org/10.1016/j.nantod.2020.100961

XXX. Feng, Q., & Chen, Y. (2022). Deep learning for nanoparticle characterization: From imaging to predictive modeling. Small Methods, 6(11), 2200657. https://doi.org/10.1002/smtd.202200657

XXXI. Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 12(11), 991–1003. https://doi.org/10.1038/nmat3776

XXXII. Ahn, J., Lee, J., & Kim, H. (2021). Artificial intelligence approaches for nanoparticle toxicity assessment: Current status and future directions. Toxicology and Applied Pharmacology, 418, 115498. https://doi.org/10.1016/j.taap.2021.115498

XXXIII. Xu, W., Ding, J., & Xu, H. (2020). Machine learning in nanomedicine: Applications, challenges, and future opportunities. Advanced Healthcare Materials, 9(17), 2001233. https://doi.org/10.1002/adhm.202001233

XXXIV. Misra, R., Acharya, S., & Sahoo, S. K. (2010). Cancer nanomedicine: A review of recent success in drug delivery. Clinical Cancer Research, 16(19), 4695–4706.https://doi.org/10.1158/1078-0432.CCR-10-0160

XXXV. Pilania, G., Wang, C., Jiang, X., Rajasekaran, S., & Ramprasad, R. (2013). Accelerating materials property predictions using machine learning. Scientific Reports, 3, 2810. https://doi.org/10.1038/srep02810